“A GLP-1 protects the kidneys” is a much shorter sentence than the research behind it. To understand what a trial actually found, it helps to ask who took part and what the researchers counted.
The FLOW study examined semaglutide in people who had both type 2 diabetes and chronic kidney disease. It found a lower rate of a combined outcome in the semaglutide group than in the placebo group. That is meaningful information for a specific population, not a guarantee that every GLP-1 medicine will prevent kidney disease in every person.
Who took part?
Researchers randomized 3,533 adults to semaglutide or placebo. Participants had type 2 diabetes and met particular kidney-function and urine-protein criteria. The median follow-up was 3.4 years.
That description is important. The study wasn’t a test of semaglutide in everyone with weight concerns, everyone with diabetes or every person with a kidney condition. People can have different causes and stages of kidney disease, and the care they need may differ.
If you’re unsure what your own diagnosis or lab results mean, ask your clinician to explain them in the context of your health history.
What was the main outcome?
FLOW used a combined, or composite, outcome. Researchers counted the first occurrence of several serious events: kidney failure, a substantial decline in estimated kidney function, or death from kidney-related or cardiovascular causes.
Combining events can help researchers answer a broader question, but it means the headline number refers to the whole group of events. It should not be described as the percentage reduction in kidney failure alone.
There were 331 first primary-outcome events in the semaglutide group and 410 in the placebo group. The reported relative reduction for the composite was 24% over the study’s follow-up. That’s a comparison between groups; it doesn’t mean an individual’s chance fell by exactly 24 percentage points.
What does a kidney-function number show?
Clinicians often use an estimated glomerular filtration rate, or eGFR, as one way to assess kidney function. Urine tests can also provide information about protein leakage. These measurements answer different questions, and one result may need context from prior tests and your broader health picture.
In FLOW, researchers also examined the rate at which estimated kidney function changed over time. That is different from counting the combined primary outcome. Both can be useful, but they shouldn’t be swapped as if they were identical measures.
Your care team can explain which tests they use for you and how often they want to repeat them. You don’t have to interpret a single result against a study chart on your own.
What can’t the study tell us?
It can’t promise an individual outcome. It also doesn’t show that the same result will occur in people without type 2 diabetes, in every stage or cause of kidney disease, or with every medicine that acts on a GLP-1 pathway.
The trial had a particular design, a specific semaglutide regimen and follow-up. Researchers also reported safety findings. Benefits, side effects and other treatments all belong in a conversation about care.
If you take a GLP-1 and have ongoing vomiting, diarrhea or trouble keeping fluids down, contact your care team for advice. Those symptoms deserve attention, particularly when you already have kidney concerns.
Questions for your next visit
You might ask: What kind of kidney disease do I have? What do my recent blood and urine tests tell us? Is the evidence from FLOW relevant to me? How will we monitor my current medicines and symptoms?
If you’re interested in an earlier point on the blood-sugar spectrum, our article on GLP-1 medicines and prediabetes covers a different set of questions.
The FLOW result applies to the group and outcome the researchers actually studied. That context is what turns an exciting headline into information you can discuss with your own care team.